EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19

Kathleen E Hurwitz, Mark Berry, EunYoung Lee, Kayla Hendrickson, Nuvan Rathnayaka, Valentina Shvachko, Mazin Abdelghany, Carrie M Nielson, M Alan Brookhart, Anand Chokkalingam, Joshua A Hill

Open Forum Infectious Diseases · 2026-10-31 · 13 (11)

DOI: 10.1093/ofid/ofag630 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Patients who were immunocompromised were largely excluded from COVID-19 clinical trials, and real-world evidence on remdesivir effectiveness has produced conflicting results. We evaluated whether early remdesivir initiation (vs late or never) reduces in-hospital mortality among patients who are immunocompromised and hospitalized with COVID-19. Methods We conducted a retrospective cohort study using a target trial emulation framework with clone-censor-weighting and deidentified hospital chargemaster data combined with medical and pharmacy claims from approximately 400 US hospitals. Patients included those who were immunocompromised, aged ≥12 years, and hospitalized for COVID-19 between 1 May 2020 and 3 December 2023. We assessed all-cause in-hospital mortality within 14 and 28 days of admission for 3 remdesivir treatment regimens: initiation within 2 days of admission (“early”), initiation within 3 to 7 days (“late”), and no initiation of remdesivir (“never”). Results Among 97 587 eligible patients (median age, 71 years; 51% female), the 14-day cumulative risk of in-hospital mortality was 9.2% for early remdesivir, 10.1% for late, and 11.8% for never. At 14 days, the adjusted relative risk was 0.91 (95% CI, .86–.97) for early vs late initiation and 0.78 (95% CI, .75–.81) for early vs never initiation. At 28 days, trends were similar. Subgroup analyses by age, variant era, and immunosuppression severity yielded similarly protective effects of early initiation of remdesivir. Conclusions The risk of in-hospital mortality for patients with COVID-19 who were immunocompromised was lower when remdesivir was administered early as compared with late or never. This result was consistent regardless of age, severity of immunosuppression, and variant era.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →